S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
S&P 500   3,853.07
DOW   31,176.01
QQQ   326.36
pixel
pixel
Log in
ASX:CYP

Cynata Therapeutics Limited (CYP.AX) Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
A$0.68
MA: A$0.68
A$0.68
52-Week Range N/A
Volume159,853 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.

MarketRank

Overall MarketRank

0.87 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 3 9824 5254
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.01 million
Book ValueA$0.14 per share

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable

Receive CYP News and Ratings via Email

Sign-up to receive the latest news and ratings for CYP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cynata Therapeutics Limited (CYP.AX) (ASX:CYP) Frequently Asked Questions

What stocks does MarketBeat like better than Cynata Therapeutics Limited (CYP.AX)?

Wall Street analysts have given Cynata Therapeutics Limited (CYP.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cynata Therapeutics Limited (CYP.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Cynata Therapeutics Limited (CYP.AX)'s earnings last quarter?

Cynata Therapeutics Limited (CYP.AX) (ASX:CYP) posted its quarterly earnings results on Wednesday, February, 27th. The company reported ($0.03) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.03).
View Cynata Therapeutics Limited (CYP.AX)'s earnings history
.

Who are some of Cynata Therapeutics Limited (CYP.AX)'s key competitors?

What other stocks do shareholders of Cynata Therapeutics Limited (CYP.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cynata Therapeutics Limited (CYP.AX) investors own include Starpharma Holdings Limited (SPL.AX) (SPL), Rigel Pharmaceuticals (RIGL), Mesoblast Limited (MSB.AX) (MSB) and Immutep Limited (IMM.AX) (IMM).

Who are Cynata Therapeutics Limited (CYP.AX)'s key executives?

Cynata Therapeutics Limited (CYP.AX)'s management team includes the following people:
  • Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 63, Pay $454.17k)
  • Dr. Kilian Kelly, Chief Operating Officer
  • Mr. Peter Gordon Webse M.A.I.C.D., B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. (Age 58, Pay $140k)
  • Dr. Suzanne Lipe, VP of Alliance Management (Age 71, Pay $217.69k)

What is Cynata Therapeutics Limited (CYP.AX)'s stock symbol?

Cynata Therapeutics Limited (CYP.AX) trades on the ASX under the ticker symbol "CYP."

How big of a company is Cynata Therapeutics Limited (CYP.AX)?

Cynata Therapeutics Limited (CYP.AX) has a market capitalization of $0.00 and generates $7.01 million in revenue each year.

What is Cynata Therapeutics Limited (CYP.AX)'s official website?

The official website for Cynata Therapeutics Limited (CYP.AX) is www.cynata.com.

How can I contact Cynata Therapeutics Limited (CYP.AX)?

The company can be reached via phone at 61 3 9824 5254.

This page was last updated on 1/22/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.